Status:
COMPLETED
Effect of Crestor on Lipoprotein Metabolism in Humans
Lead Sponsor:
Foundation for Atlanta Veterans Education and Research, Inc.
Collaborating Sponsors:
AstraZeneca
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
50-75 years
Phase:
PHASE4
Brief Summary
The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate th...
Detailed Description
Crestor has been demonstrated to be effective in reducing plasma LDL by 20 to 60% in a dose dependent fashion. While the primary mechanism of action of this class of agents is the increase in the expr...
Eligibility Criteria
Inclusion
- TG between 200 and 400 mg/dL
- LDLc between 160 and 250 mg/dL
- HDLc between 30 and 50 mg/dL for men and 40-65 mg/dL for women
- Lp(a) less than 30 mg/dL
- Age between 50 and 75 years
Exclusion
- current lipid-lowering therapy,
- primary hypertriglyceridemia (TG\>400 mg/dL),
- High HDL (HDL\>70),
- high Lp(a), greater than 30 mg/dL
- presence of beta-VLDL on agarose electrophoresis,
- current use of immunosuppressive agents,
- hormone replacement therapy for women
- history of cancer, active liver disease or hepatic dysfunction (AST or ALT 1.5 x ULN (Upper Limit of Normal),
- excessive consumption of alcohol, and recent history of drug abuse.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00214617
Start Date
January 1 2005
End Date
February 1 2006
Last Update
June 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta Research and Education Foundation
Decatur, Georgia, United States, 30033